Companies › Tiziana Life Sciences
1 active drug program in 4 registered trials: 4 Phase 2; Neurology; next expected readout Apr 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Foralumab (TZLS-401) T cell surface glycoprotein CD3 inhibitor | CD3E, CD3G, CD3D | Phase 2 | Non-Active Secondary Progressive Multiple Sclerosis; Secondary Progressive Multiple Sclerosis; Multiple System Atrophy; Dementia | Apr 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06890923 | Foralumab (TZLS-401) | Phase 2 | Non-Active Secondary Progressive Multiple Sclerosis | Neurology | Apr 2026 |
| NCT06292923 | Foralumab (TZLS-401) | Phase 2 | Secondary Progressive Multiple Sclerosis | Neurology | Sep 2026 |
| NCT06489548 | Foralumab (TZLS-401) | Phase 2 | Dementia | Neurology | Dec 2026 |
| NCT06868628 | Foralumab (TZLS-401) | Phase 2 | Multiple System Atrophy | Neurology | Apr 2027 |
Johnson & Johnson (Janssen) Amgen Roche Regeneron Pharmaceuticals Pfizer Genmab AstraZeneca Sanofi Shine-On Biomedical Cullinan Therapeutics
Abcuro Keros Therapeutics Acumen Pharmaceuticals Dianthus Therapeutics Y-mAbs Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.